Be Aware of New Safety Issues With Xeljanz
Safety concerns are stacking up with tofacitinib (Xeljanz, Xeljanz XR) for rheumatoid arthritis and other autoimmune diseases.
Xeljanz and other "Janus kinase (JAK) inhibitors" are already linked to blood clots...serious infections...and other issues.
Now FDA is warning that Xeljanz may increase the risk of heart attacks and other serious cardiovascular (CV) events. There are also more data that it increases the risk of cancer.